US Patent 9,943,515: Netupitant Five-Day Antiemetic Regimen, Claim Scope and Patent Landscape

US Patent No. 9,943,515 protects methods using a single day-one dose of netupitant to treat chemotherapy-induced nausea and vomiting, or other emesis, across acute and delayed phases for five consecutive days. Its broadest issued claim does not require a specific receptor-occupancy threshold, chemotherapy agent, oral route, or dexamethasone combination. The patent issued April 17, 2018, and has a projected expiration in late 2033 based on its underlying priority and statutory term.[1]

The commercial relevance is concentrated in Akynzeo, the fixed-dose netupitant/palonosetron product marketed by Helsinn Healthcare SA and its commercial partners. The patent is a small-molecule method-of-use patent, not a biologic patent. Biosimilar procedures therefore do not apply. Any competing netupitant product would generally proceed through the abbreviated new drug application, or ANDA, pathway.

What does US Patent 9,943,515 protect?

The patent covers a five-day antiemetic treatment regimen in which:

netupitant is administered once on day one;
no further netupitant is administered during days one through five;
the single dose treats nausea and vomiting during both acute and delayed phases;
the treatment follows an emesis-inducing event, including chemotherapy;
certain claims require central nervous system NK1 receptor occupancy at 72 or 96 hours.

The broadest method is claim 11. It requires a single therapeutically effective dose on day one and efficacy over five consecutive days, but it does not require the pharmacokinetic limitation in claim 1.

Core claim architecture

Claim group	Principal limitation	Commercial significance
Claims 1-2	Five-day treatment, single day-one dose, acute and delayed efficacy, 70% or 80% striatal NK1 occupancy at 72 hours	Protects the pharmacodynamic rationale for extended netupitant activity
Claims 3-4	Netupitant plus reduced dexamethasone doses	Protects a steroid-sparing combination regimen
Claims 5-8	CINV, RINV, PONV, moderately or highly emetogenic chemotherapy, acute and delayed phases	Defines therapeutic settings
Claims 9-10	Approximately 200-400 mg, particularly 300 mg orally	Tracks the commercial netupitant dose
Claims 11-13	Broad five-day single-dose regimen, including 200-400 mg and 300 mg	The principal broad method-of-use claims
Claims 14-16	Specific highly, moderately, or broadly emetogenic chemotherapy agents	Narrows infringement to listed chemotherapy regimens
Claims 17-18	CINV defined by no emesis and no rescue medication; 70% NK1 occupancy at 96 hours	Adds a clinical endpoint and extended receptor-occupancy limitation
Claims 19-23	Highly or moderately emetogenic chemotherapy and specified agents	Provides event-specific fallback positions

Which claims are the broadest in US Patent 9,943,515?

Claim 11 is the broadest practical claim because it omits the 70% striatal NK1 receptor-occupancy requirement found in claim 1. It requires:

treatment of nausea and vomiting caused by an emesis-inducing event;
treatment for five consecutive days;
administration of a therapeutically effective amount of netupitant or a salt;
administration on day one;
no further netupitant during the five-day period; and
effectiveness of that single dose across the five-day period.

Claim 11 does not expressly require:

oral administration;
300 mg;
chemotherapy;
dexamethasone;
a particular chemotherapy drug;
70% or 80% NK1 receptor occupancy;
a particular formulation;
a fixed-dose netupitant/palonosetron product.

That breadth creates the principal infringement exposure for a competing netupitant product using a one-time dose intended to control delayed nausea and vomiting.

Claim 1 compared with claim 11

Issue	Claim 1	Claim 11
Five-day treatment	Required	Required
Single day-one dose	Required	Required
No further netupitant for five days	Required	Required
Acute and delayed efficacy	Required	Required
Striatal NK1 occupancy	At least 70% at 72 hours	Not required
Chemotherapy required	No	No
Oral route required	No	No
300 mg required	No	No
Dexamethasone required	No	No

Claims 1 and 11 overlap substantially. Claim 1 supplies a measurable pharmacodynamic limitation. Claim 11 is easier to assert against a product label or clinical protocol if the five-day efficacy and dosing instructions are clear, but it may face greater validity scrutiny because “effective” treatment over five days is stated without the receptor-occupancy limitation.

How does the 300 mg netupitant limitation affect the patent scope?

Claims 4, 10, and 13 specifically cover approximately 300 mg of netupitant free base. Claims 9 and 12 cover the broader 200-400 mg range.

The 300 mg limitation aligns closely with the netupitant component in Akynzeo. FDA labeling identifies Akynzeo as a fixed-dose oral capsule containing netupitant 300 mg and palonosetron 0.5 mg.[2]

A product using 300 mg netupitant once before chemotherapy would fall within the literal scope of claims 10 and 13 if the product also satisfies the five-day efficacy and no-redosing conditions. A lower or higher dose could remain within claim 11, provided the single dose is therapeutically effective for five days.

The patent therefore has two different enforcement layers:

a dose-specific layer centered on 300 mg;
a broader regimen layer covering an effective single dose within or outside the 200-400 mg range.

What does the patent require regarding dexamethasone?

Claims 3 and 4 cover a reduced-dexamethasone regimen used with netupitant.

Claim 3 requires:

a day-one dexamethasone dose equal to 50-70% of the minimum effective dose when dexamethasone is used alone; and
for highly emetogenic chemotherapy, dexamethasone on days two through four equal to 40-60% of the standalone minimum effective dose.

Claim 4 provides concrete amounts:

approximately 12 mg of dexamethasone on day one;
approximately 8 mg on days two, three, and four for highly emetogenic chemotherapy;
one approximately 300 mg netupitant dose on day one.

These claims do not expand the core patent to every netupitant-dexamethasone regimen. They require the specific reduced-dose concept and, for claim 4, the stated dosing schedule.

FDA labeling for Akynzeo includes dexamethasone as part of the antiemetic regimen and recommends a reduced dexamethasone dose because netupitant inhibits CYP3A4 and can increase dexamethasone exposure.[2] The label and the patent therefore overlap commercially, although label language alone does not determine infringement.

What chemotherapy events are covered?

Claims 14-16 identify chemotherapy agents by emetogenicity.

Highly emetogenic chemotherapy

Claim 14 lists:

carmustine;
cisplatin;
cyclophosphamide at least 1,500 mg/m²;
dacarbazine;
dactinomycin;
mechlorethamine;
streptozotocin; and
combinations of those agents.

Moderately emetogenic chemotherapy

Claim 15 lists:

carboplatin;
cyclophosphamide below 1,500 mg/m²;
cytarabine above 1 mg/m²;
daunorubicin;
doxorubicin;
epirubicin;
idarubicin;
ifosfamide;
irinotecan; and
oxaliplatin.

Claims 21-23 provide narrower event-specific coverage for cisplatin, carboplatin, oxaliplatin, doxorubicin, and cyclophosphamide.

The chemotherapy lists are important for litigation because they create narrower fallback claims if the broad five-day regimen claims are challenged. A generic or branded competitor could avoid claims 14-16 by targeting an event outside the listed agents, but it could still face claims 11-13 if its product label supports the broader regimen.

What is the pharmacodynamic significance of the NK1 receptor claims?

Netupitant is a neurokinin-1, or NK1, receptor antagonist. The patent links sustained antiemetic activity to occupancy of NK1 receptors in the striatum.

The relevant thresholds are:

at least 70% occupancy at 72 hours in claim 1;
at least 80% occupancy at 72 hours in claim 2; and
at least 70% occupancy at 96 hours in claim 18.

These limitations attempt to distinguish a long-acting single-dose regimen from repeated dosing or shorter-acting NK1 antagonism. The receptor-occupancy language can support infringement where clinical or pharmacokinetic data establish the threshold. It also creates a technical validity issue because the claim depends on a measured biological parameter that may vary by imaging method, patient population, timing, and analytical protocol.

Claims 1 and 2 require occupancy in the striatum, not merely systemic exposure or plasma half-life. A product could have a long plasma half-life without necessarily meeting the claimed striatal occupancy threshold.

How strong is the patent estate for netupitant?

The estate is strongest against a product that reproduces the commercial regimen:

oral netupitant;
approximately 300 mg;
a single dose on day one;
treatment of acute and delayed CINV;
use with moderately or highly emetogenic chemotherapy;
dexamethasone on day one and, for highly emetogenic chemotherapy, on days two through four.

The strongest commercial claims are claims 10, 13, 19, 20, and 21-23 when the product label expressly identifies the corresponding dose, duration, chemotherapy, and clinical objective.

Strength assessment by limitation

Limitation	Enforcement value	Principal vulnerability
Single dose on day one	High	May be avoided by a different dosing schedule
No further netupitant for five days	High	Label and actual-use proof may diverge
Acute and delayed efficacy	High	Clinical evidence and label wording are important
300 mg oral dose	High	Strong alignment with Akynzeo
200-400 mg range	Moderate to high	Potential prior-art and written-description issues
70% NK1 occupancy	Moderate	Requires reliable patient-level or population-level proof
Five-day effectiveness	Moderate	“Effective” may invite claim-construction disputes
Reduced dexamethasone regimen	High but narrow	Requires proof of the percentage or specified amounts
Listed chemotherapy agents	High but narrow	Does not cover unlisted emesis-inducing events

The broad method claims may be more commercially valuable than the receptor-occupancy claims because a competitor’s label may describe the dosing schedule and treatment period without disclosing receptor-occupancy data.

When does US Patent 9,943,515 lose exclusivity?

US Patent 9,943,515 issued April 17, 2018. Its projected statutory expiration is in late 2033, generally reported as November 29, 2033, subject to any applicable patent-term adjustment or extension reflected in the USPTO record.[1]

The patent’s effective commercial exclusivity may end earlier if:

the patent is invalidated;
claims are canceled in post-grant proceedings;
a court finds noninfringement;
a generic settlement permits an earlier launch; or
an ANDA applicant uses a noninfringing label and regimen.

The patent does not provide regulatory exclusivity by itself. FDA exclusivity and patent protection are separate mechanisms.

What is the FDA and Orange Book status of the protected product?

Akynzeo is FDA-approved for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy and moderately emetogenic cancer chemotherapy.[2]

The product contains:

netupitant, 300 mg;
palonosetron, 0.5 mg;
oral capsule dosage form.

The relevant regulatory pathway is an NDA for the fixed-dose combination. A generic applicant seeking approval of an equivalent product would ordinarily file an ANDA and address listed patents through Paragraph I, II, III, or IV certifications under the Hatch-Waxman framework.[3]

The Orange Book must be checked for the current listing status, patent-use codes, and any later-listed patents. Patent 9,943,515 is associated with the Akynzeo patent estate, but an Orange Book listing does not establish claim validity or infringement. It gives the NDA holder a mechanism to assert a listed patent after a Paragraph IV notice.

Paragraph IV exposure

A Paragraph IV certification against a listed method-of-use patent can trigger patent litigation if the NDA holder or patent owner files suit within the statutory period. The principal dispute would likely focus on whether the proposed generic label:

directs a single netupitant dose on day one;
claims prevention or treatment through the delayed phase;
covers five days of treatment;
includes the relevant chemotherapy regimens; or
uses the patented dexamethasone schedule.

A “skinny label” may reduce exposure if it carves out the patented method. That strategy is difficult where the approved use, dosing frequency, and delayed-phase indication are inseparable from the patented regimen.

Which companies are challenging or competing with the patent?

The principal competitive risk comes from generic manufacturers seeking to market netupitant/palonosetron or a therapeutically equivalent antiemetic regimen through the ANDA pathway. Public litigation status, ANDA filer identity, and settlement terms must be evaluated from the latest PACER docket, FDA Orange Book, and FDA Paragraph IV records.

The competitive landscape also includes products that do not contain netupitant:

Product or class	Active ingredient	Competitive relationship
Akynzeo	Netupitant/palonosetron	Direct product protected by the regimen
Emend	Aprepitant	Alternative NK1 antagonist
Fosaprepitant	Fosaprepitant dimeglumine	Intravenous prodrug of aprepitant
Varubi	Rolapitant	Alternative long-acting NK1 antagonist
Aloxi	Palonosetron	5-HT3 antagonist, often used in combination
Generic aprepitant products	Aprepitant	Lower-cost alternative antiemetic
Generic palonosetron products	Palonosetron	Alternative or combination component

Aprepitant, fosaprepitant, and rolapitant do not automatically infringe Patent 9,943,515 because the claims require netupitant or a pharmaceutically acceptable salt thereof.

Are biosimilars a risk to this patent?

No. Netupitant and palonosetron are chemically synthesized small molecules. A competing product would not be a biosimilar under the Public Health Service Act. It would generally be an ANDA product demonstrating pharmaceutical equivalence, bioequivalence, and compliance with applicable labeling requirements.[3]

The relevant risks are:

ANDA approval;
Paragraph IV patent challenges;
label carve-outs;
formulation differences;
alternative dosing schedules; and
post-settlement launch timing.

What formulations and manufacturing rights are protected?

Patent 9,943,515 is principally a method-of-treatment patent. The claims supplied do not directly claim:

a capsule composition;
a particular polymorph;
a tablet or capsule excipient system;
a solid dispersion;
a manufacturing process;
a salt-selection process;
a particle-size distribution; or
the netupitant/palonosetron composition as such.

Those rights must be reviewed in separate patents and patent families covering netupitant, palonosetron, fixed-dose combinations, pharmaceutical compositions, crystalline forms, and manufacturing processes.

A competing manufacturer could therefore avoid this patent by using a different formulation only if it also avoids the claimed method. A formulation change alone would not avoid infringement if the product is still directed to the same single-dose, five-day netupitant regimen.

What patent litigation and settlement issues matter?

The central litigation questions are likely to be:

Whether claim 11 requires proof of actual five-day efficacy in every patient or only that the regimen is therapeutically effective as a treatment method.
Whether a product label that recommends one dose before chemotherapy necessarily induces practice of the five-day method.
Whether “no further netupitant” is satisfied when a patient receives another NK1 antagonist.
Whether “acute and delayed phases” supplies an objective clinical limitation.
Whether the receptor-occupancy limitations are definite and adequately supported.
Whether prior art disclosed single-dose netupitant treatment for delayed CINV.
Whether the dexamethasone percentage limitations are sufficiently definite and enabled.

Any settlement could establish a licensed generic launch date before the patent’s nominal expiration. A settlement may also distinguish between an authorized generic, a licensed fixed-dose product, and an independent generic with a carved-out label. No settlement should be treated as confirming validity unless its terms or a final judgment say so.

How does Patent 9,943,515 compare with competing antiemetic patent estates?

Patent 9,943,515 differs from older NK1-antagonist estates because its center of gravity is regimen duration and single-dose persistence rather than merely the chemical compound.

Estate type	Typical protected subject matter	Relationship to 9,943,515
Netupitant compound patents	Chemical structure, salts, intermediates	May create earlier barriers to netupitant itself
Akynzeo combination patents	Netupitant plus palonosetron	Can block the fixed-dose combination independently
Netupitant regimen patents	Single-dose acute and delayed CINV treatment	Directly overlaps Patent 9,943,515
Aprepitant patents	Different NK1 compound and uses	Competitive but generally non-overlapping
Palonosetron patents	5-HT3 antagonist compound and formulations	Relevant to the combination product
Rolapitant patents	Different NK1 compound	Alternative therapy, not a direct infringement route

The commercial patent risk therefore depends on the full family, not Patent 9,943,515 alone. A generic may avoid this patent but remain blocked by separate composition, combination, formulation, or manufacturing patents.

What generic launch scenarios exist?

Scenario 1: Launch after patent expiry

A generic launches after all relevant listed patents expire or are otherwise removed. This is the lowest litigation-risk scenario but may occur after 2033 if later patents protect the product.

Scenario 2: Paragraph IV challenge

An ANDA filer argues that Patent 9,943,515 is invalid, unenforceable, or not infringed. Litigation can delay approval or launch. The key technical defenses would focus on prior art, definiteness, written description, enablement, and the meaning of “effective” for five consecutive days.

Scenario 3: Carved-out label

The applicant removes patented method-of-use language. This may reduce infringement exposure, but the strategy is difficult if the remaining label still directs the same single-dose regimen for delayed CINV.

Scenario 4: Licensed launch

The applicant settles with the patent owner and receives a contractually defined launch date. The settlement may include supply, licensing, or authorized-generic provisions.

Scenario 5: Non-netupitant substitution

A competitor markets aprepitant, fosaprepitant, rolapitant, or another antiemetic. This avoids the active-ingredient limitation but competes for the same CINV market.

What is the revenue exposure?

The patent’s economic exposure is tied to the netupitant/palonosetron CINV market, particularly patients receiving moderately or highly emetogenic chemotherapy. The highest-value protected use is the oral, single-dose regimen that covers both acute and delayed phases and reduces the need for additional NK1 dosing.

Revenue exposure should be modeled against:

US Akynzeo sales;
net price after rebates;
oncology clinic and hospital channel mix;
generic substitution rates;
availability of aprepitant and fosaprepitant;
payer formulary restrictions;
any authorized generic;
launch timing under litigation settlements; and
later-expiring formulation or combination patents.

Patent 9,943,515 alone does not establish the complete US loss-of-exclusivity date. The controlling date is the latest enforceable barrier applicable to the commercial product and proposed generic.

Key Takeaways

US Patent 9,943,515 protects a single day-one netupitant dose intended to control nausea and vomiting for five consecutive days.
Claim 11 is the broadest issued method claim because it does not require 70% striatal NK1 receptor occupancy.
Claims 9, 10, 12, and 13 target the commercial 200-400 mg range and approximately 300 mg dose.
Claims 3 and 4 protect reduced-dose dexamethasone combinations.
Claims 14-16 and 21-23 narrow protection to specified chemotherapy agents.
The patent is relevant to Akynzeo, the netupitant 300 mg/palonosetron 0.5 mg fixed-dose product.
Generic challengers would use the ANDA and Paragraph IV framework, not the biosimilar pathway.
The projected patent expiration is late 2033, generally reported as November 29, 2033, subject to the USPTO-recorded term.
The ultimate generic launch date depends on the entire Akynzeo patent estate, litigation outcomes, settlements, and any later-listed patents.

FAQs

Does Patent 9,943,515 cover netupitant as a chemical compound?

No. The supplied claims are method claims. They require administering netupitant for a defined antiemetic treatment regimen. Separate compound, formulation, combination, salt, polymorph, and manufacturing patents may provide additional protection.

Can a generic avoid Patent 9,943,515 by administering netupitant more than once?

Potentially, but the answer depends on the complete claim set and product instructions. Repeated dosing could avoid the express “single dose” and “no further netupitant” limitations, while still raising issues under other patents.

Does use of palonosetron avoid the patent?

No. The claims require netupitant but do not require or exclude palonosetron. A netupitant/palonosetron product can fall within the claims if it satisfies the dosing and five-day treatment limitations.

Is the five-day period the same as five days of netupitant dosing?

No. The claims require only one netupitant dose on day one and no further netupitant during the five-day period. The five-day period describes the intended duration of treatment effectiveness.

Are the chemotherapy-agent lists exhaustive for the broadest claim?

No. Claims 14-16 and 21-23 list specific chemotherapy events, but claim 11 refers more broadly to an “emesis-inducing event.” A product may therefore face claim 11 even when the chemotherapy agent is not listed in the narrower claims.

References

United States Patent and Trademark Office. (2018). U.S. Patent No. 9,943,515, Method of treating nausea and vomiting.
U.S. Food and Drug Administration. (2023). Akynzeo (netupitant and palonosetron) prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Helsinn Hlthcare	AKYNZEO	netupitant; palonosetron hydrochloride	CAPSULE;ORAL	205718-001	Oct 10, 2014		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	3083	⤷ Start Trial
Australia	2010320598	⤷ Start Trial
Brazil	112012011485	⤷ Start Trial
Canada	2778301	⤷ Start Trial
Chile	2012001276	⤷ Start Trial
China	102655864	⤷ Start Trial
China	104856998	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 9,943,515